What is the prevalence of Myelodysplastic Syndromes?

Myelodysplastic Syndromes (MDS) are a group of diverse bone marrow disorders with an estimated prevalence of 30 to 50 per 100,000 people, though rates are significantly higher in populations over age 70. While often classified as rare, the true incidence is likely higher than reported due to the challenges of diagnosing milder, asymptomatic cases in older adults.

How common are Myelodysplastic Syndromes?

Myelodysplastic Syndromes are considered rare in the general population, but their frequency increases dramatically with age. According to data from the NIH GARD and Orphanet, the annual incidence is approximately 4 to 5 cases per 100,000 individuals, rising to over 30 per 100,000 in those aged 70 and older. Currently, 36 members of the DiseaseMaps.org community have shared their experiences with Myelodysplastic Syndromes, highlighting the importance of patient-reported data in understanding the real-world impact of these conditions.

What factors influence the prevalence of Myelodysplastic Syndromes?

Several demographic and clinical factors impact how frequently Myelodysplastic Syndromes are identified:

• Age: The median age of diagnosis for Myelodysplastic Syndromes is approximately 70–75 years, making it primarily a disease of older adulthood.


• Gender: Clinical literature suggests a slight male predominance in the diagnosis of Myelodysplastic Syndromes.


• Geographic/Ethnic Variation: While global data is limited, some studies suggest variations in incidence based on environmental exposures and genetic predispositions across different populations.


• Diagnostic Challenges: Underdiagnosis remains a major hurdle, as early-stage Myelodysplastic Syndromes may present with mild anemia that is often attributed to other age-related conditions.

Why is accurate data for Myelodysplastic Syndromes difficult to obtain?

Tracking the prevalence of Myelodysplastic Syndromes is complex because registries often rely on hospital-based data, which may miss patients who are managed in outpatient settings without a definitive bone marrow biopsy. Furthermore, because Myelodysplastic Syndromes can evolve into acute myeloid leukemia, some cases may be reclassified over time, leading to discrepancies in reporting.

Next steps

• Consult a hematologist or an oncologist specializing in bone marrow failure syndromes.


• Review your blood counts periodically if you are at high risk or have unexplained cytopenias.


• Join the DiseaseMaps.org community to connect with others navigating a diagnosis of Myelodysplastic Syndromes.


• Discuss clinical trial eligibility with your specialist to access emerging therapies.

Medical disclaimer: This content is for informational purposes only and does not constitute professional medical advice, diagnosis, or treatment; always seek the advice of your physician.

References

• NIH Genetic and Rare Diseases Information Center (GARD): Myelodysplastic syndromes.


• Orphanet: Myelodysplastic syndrome (ORPHA:589).


• The Myelodysplastic Syndromes Foundation: Understanding MDS prevalence.


• National Cancer Institute (NCI): Surveillance, Epidemiology, and End Results (SEER) Program.